News

This invention is for a nanotechnology process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid nanosomes for use in combination therapy by means of Aphios’ SuperFluids technology

The territory covers China including Mainland China, Taiwan, Hong Kong and Macau as well as other countries, including Thailand, Brazil and Russia. 3SBio president and CEO Dr Jing

Harvoni is a combination of the NS5A inhibitor ledipasvir (LDV) and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and is indicated to treat adults with chronic hepatitis C

The US Food and Drug Administration (FDA) approval of Trumenba is based on the demonstration of immune response, as measured by serum bactericidal activity against four serogroup B

The approval is based on positive data from the Phase III VIVID-DME and VISTA-DME trials and one open label single arm safety trial in Japanese patients (VIVID-Japan). During

Both the firms have not been disclosed financial details of the agreement. Aspen has agreed to specific annual commercial goals for Brinavess. Cardiome chief commercial officer Karim Lalji

The randomized, observer-blinded, dose-ranging trial will evaluate the safety and immunogenicity of the Seasonal Influenza VLP in 400 healthy adult subjects. The trial’s primary outcomes will be to

This announcement follows the successful testing of DCR-PH1 in combination with Tekmira’s LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay

KTE-C19 is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient’s T cells to express a CAR that is designed to target CD19, a protein